The Ford Coyote 5.0 V8 has been around since 2010, and the current version of the Chevrolet LT1 6.2 V8 premiered in 2013.

The inline-six engine offers some significant advantages against V-block engines, but these same engineering differences also ...

BERN, June 15 - Swiss financial crime prosecutors are racing against time as outdated regulation in one of the world's top cross-border wealth management centres allows defendants to drag out rulings, ...

Swiss Crackdown on White-Collar Crime Has a Timing Problem, Prosecutor Says By Ariane Luthi BERN, June 15 (Reuters) - Swiss financial crime prosecutors are racing against time as outdated ⁠regulation ...

Many of today’s cars last for 200,000 miles or more with few, if any, major repairs. CR shares its research and advice on how to make your car last.

The biggest story of the week is a new massive supply chain breach, which appears to be unrelated to the previous massive supply chain breaches, this time of the Axios HTTP project. Axios was created ...

Ken Ammon is CEO of CodeHunter, a serial entrepreneur who exited OPĀQ and NetSec, and former U.S. Air Force captain at the NSA. Enterprise security is built on a flawed assumption that we can ...

Where the field convenes. Privately. A curated private community for credentialed ethics, risk, and compliance leaders across the ECI and Compliance Week network. Ask the questions you can’t post ...

The global chip sector is under heightened pressure around supply chains and costs as the fallout from the Iran war continues. While an AI rally continues to boost stocks, a prolonged conflict would ...

The UK continues to experience shortages of many common prescription drugs, despite efforts to strengthen supply chains. As products become unavailable, pressure increases across the system to secure ...

The promise of smart test is a data-chain problem before it is an algorithm problem. A device can pass every checkpoint and still carry a latent defect the test record never captured. As test grows ...

A recently published paper delivers a finding that should be well known to every executive in Western pharma: China has gone from accounting for less than 8% of global clinical trials in 2010 to ...